# ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

> **NCT00396240** · PHASE4 · WITHDRAWN · sponsor: **AstraZeneca** · enrollment: 1294 (—)

## Conditions studied

- Primary Hypercholesterolaemia

## Interventions

- **DRUG:** Rosuvastatin
- **PROCEDURE:** Initiatives to improve compliance

## Key facts

- **NCT ID:** NCT00396240
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2002-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 1294 (—)
- **Why stopped:** study cancelled prior to FSI
- **Last updated:** 2009-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00396240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00396240, "ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00396240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*